title: Developing guidelines for venous thromboembolism for The National Institute for Clinical Excellence: involvement of the orthopaedic surgical panel.
abstract: Following the publication in 2007 of the guidelines from the National Institute for Health and Clinical Excellence (NICE) for prophylaxis against venous thromboembolism (VTE) for patients undergoing surgery, concerns were raised by British orthopaedic surgeons as to the appropriateness of the recommendations for their clinical practice. In order to address these concerns NICE and the British Orthopaedic Association agreed to engage a representative panel of orthopaedic surgeons in the process of developing expanded VTE guidelines applicable to all patients admitted to hospital. The functions of this panel were to review the evidence and to consider the applicability and implications in orthopaedic practice in order to advise the main Guideline Development Group in framing recommendations. The panel considered both direct and indirect evidence of the safety and efficacy, the cost-effectiveness of prophylaxis and its implication in clinical practice for orthopaedic patients. We describe the process of selection of the orthopaedic panel, the evidence considered and the contribution of the panel to the latest guidelines from NICE on the prophylaxis against VTE, published in January 2010.
authors.affiliation: Department of Mathematics, University College, 4 Taviton Street, London WC1H 0BT, UK. tom.treasure@gmail.com
authors.forename: T
authors.initials: T
authors.lastname: Treasure
authors.forename: L-Y
authors.initials: LY
authors.lastname: Chong
authors.forename: C
authors.initials: C
authors.lastname: Sharpin
authors.forename: D
authors.initials: D
authors.lastname: Wonderling
authors.forename: K
authors.initials: K
authors.lastname: Head
authors.forename: J
authors.initials: J
authors.lastname: Hill
mesh_terms: D000925:Anticoagulants / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D019643:Arthroplasty, Replacement / Q000009:adverse effects*; D003362:Cost-Benefit Analysis; D019317:Evidence-Based Medicine / Q000379:methods*; D006470:Hemorrhage / Q000139:chemically induced / Q000453:epidemiology; D006801:Humans; D015201:Meta-Analysis as Topic; D009985:Orthopedics / Q000191:economics / Q000592:standards*; D010560:Personnel Selection / Q000379:methods; D017410:Practice Guidelines as Topic; D016032:Randomized Controlled Trials as Topic; D018570:Risk Assessment; D017751:Safety Management; D012955:Societies, Medical; D016896:Treatment Outcome; D006113:United Kingdom / Q000453:epidemiology; D014481:United States; D054556:Venous Thromboembolism / Q000191:economics / Q000401:mortality / Q000517:prevention & control*
chemical_list: D000925:Anticoagulants